VERVE THERAPEUTICS INC (VERV)
US92539P1012 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to VERV. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 32.77. This target is 411.19% above the current price.
VERV was analyzed by 17 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about VERV.
In the previous month the buy percentage consensus was at a similar level.
VERV was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-03 | Stifel | Maintains | Buy -> Buy |
| 2024-02-28 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-09-13 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-08-29 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-11 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-06-16 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2023-05-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-04-13 | Canaccord Genuity | Initiate | Buy |
| 2023-02-01 | Cantor Fitzgerald | Initiate | Neutral |
| 2022-12-15 | Goldman Sachs | Initiate | Sell |
| 2022-11-08 | RBC Capital | Maintains | Outperform |
| 2022-10-06 | Credit Suisse | Initiate | Neutral |
| 2022-08-25 | Stifel | Upgrade | Hold -> Buy |
| 2022-07-18 | BMO Capital | Maintains | Outperform |
| 2022-06-17 | BMO Capital | Initiate | Outperform |
| 2022-02-18 | RBC Capital | Initiate | Outperform |
| 2021-09-24 | Stifel | Initiate | Hold |
| 2021-07-12 | Guggenheim | Initiate | Buy |
| 2021-07-12 | William Blair | Initiate | Outperform |
| 2021-07-12 | JP Morgan | Initiate | Neutral |
| 2021-07-12 | Jefferies | Initiate | Buy |